Pharmacoepidemiology and drug safety · 2025
Use of Valproic Acid Among Women of Childbearing Age and Its Concomitant Use With Contraceptives in Colombia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Machado-Alba Jorge E, Gaviria-Mendoza Andrés, Machado-Duque Manuel E, Valladales-Restrepo Luis F, Figueras Albert
Аннотация
PURPOSE: Valproic acid is a known teratogen. The aim was to identify contraceptive use in a group of women using valproic acid.
METHODS: Descriptive study. A total of 22 855 women of childbearing age (15-49 years) with at least 1 month of valproic acid use from January 2022 to December 2023 were selected from a Colombian drug-dispensing database. Data on the dispensing of hormonal contraceptives were searched during the study period. The time and rate of coverage (% of the period during which women took contraceptives while using valproic acid/total period of valproic acid consumption) with contraceptives were calculated.
RESULTS: Among the women included, 71.4% (n = 16 308) used 250-mg valproic acid tablets. The mean age was 32.7 (standard deviation [SD]: 9.9) years, and the most common related diagnosis was migraine and headache (n = 5163, 22.6%). Only 8.0% (n = 1832) of the women had at least 1 day of coverage with some contraceptive while using valproate. For the patients with at least 1 day of coverage, the average duration of coverage was 72.5 (SD: 84.7) days (median: 30 days; IQR: 30-86 days). This represents an overall coverage rate of 5.3% (SD: 20.4%) (median: 0.0) and a coverage rate of 65.7% (SD: 35.1%) (median: 75.8%, IQR: 33.3-100%) for those with at least 1 day of coverage.
CONCLUSIONS: A significant proportion of women of childbearing age are likely at risk of becoming pregnant while taking valproic acid.
METHODS: Descriptive study. A total of 22 855 women of childbearing age (15-49 years) with at least 1 month of valproic acid use from January 2022 to December 2023 were selected from a Colombian drug-dispensing database. Data on the dispensing of hormonal contraceptives were searched during the study period. The time and rate of coverage (% of the period during which women took contraceptives while using valproic acid/total period of valproic acid consumption) with contraceptives were calculated.
RESULTS: Among the women included, 71.4% (n = 16 308) used 250-mg valproic acid tablets. The mean age was 32.7 (standard deviation [SD]: 9.9) years, and the most common related diagnosis was migraine and headache (n = 5163, 22.6%). Only 8.0% (n = 1832) of the women had at least 1 day of coverage with some contraceptive while using valproate. For the patients with at least 1 day of coverage, the average duration of coverage was 72.5 (SD: 84.7) days (median: 30 days; IQR: 30-86 days). This represents an overall coverage rate of 5.3% (SD: 20.4%) (median: 0.0) and a coverage rate of 65.7% (SD: 35.1%) (median: 75.8%, IQR: 33.3-100%) for those with at least 1 day of coverage.
CONCLUSIONS: A significant proportion of women of childbearing age are likely at risk of becoming pregnant while taking valproic acid.